Xenon PharmaceuticalsXENE +4.67%25 3-Year RORE % is 18.70 as of Mar. 2026. GuruFocus rates XENE with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 1,288 Biotechnology companies, Xenon Pharmaceuticals ranks better than 79.66% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Xenon Pharmaceuticals's 3-Year RORE % for the quarter that ended in Mar. 2026 was 18.70%.
The industry rank for Xenon Pharmaceuticals's 3-Year RORE % or its related term are showing as below:
XENE's 3-Year RORE % is ranked better than 79.66% of 1288
companies
in the Biotechnology industry
Industry Median: -11.485
vs XENE: 18.70
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Xenon Pharmaceuticals 3-Year RORE % Related Terms
Xenon Pharmaceuticals 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Xenon Pharmaceuticals's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XENE vs DFTX, LEGN, TVTX: 3-Year RORE % Comparison
For the Biotechnology subindustry, Xenon Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenon Pharmaceuticals 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Xenon Pharmaceuticals's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Xenon Pharmaceuticals (XENE) has a 3-Year RORE % of 18.70 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Xenon Pharmaceuticals and its competitors. According to the industry distribution chart, Xenon Pharmaceuticals ranks #262 out of 1288 companies in the Biotechnology industry, placing it in the top 20.3%.
Is Xenon Pharmaceuticals' 3-Year RORE % too high?
Xenon Pharmaceuticals' current 3-Year RORE % is 18.70. Based on the distribution chart, Xenon Pharmaceuticals ranks #262 out of 1288 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xenon Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Xenon Pharmaceuticals' 3-Year RORE % compare to DFTX and LEGN?
According to the Biotechnology industry distribution chart, Xenon Pharmaceuticals ranks #262 out of 1288 companies for 3-Year RORE %. This places Xenon Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Xenon Pharmaceuticals and its competitors. Xenon Pharmaceuticals's current 3-Year RORE % is 18.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenon Pharmaceuticals stock overvalued right now?
Xenon Pharmaceuticals (XENE) has a current 3-Year RORE % of 18.70. The current 3-Year RORE % is 18.70. Xenon Pharmaceuticals' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Xenon Pharmaceuticals (XENE), the current 3-Year RORE % is 18.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
25GF Score
Get the complete analysis for XENE
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XENE has been successfully added to your 
